<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952003</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT GASTRIC-3</org_study_id>
    <nct_id>NCT00952003</nct_id>
  </id_info>
  <brief_title>Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients</brief_title>
  <official_title>Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy of an Oxaliplatin /&#xD;
      Irinotecan / Bevacizumab therapy followed by Docetaxel / Bevacizumab therapy followed by&#xD;
      Bevacizumab until progression in the treatment of locally advanced metastatic gastric cancer,&#xD;
      in terms of response rates (complete or partial response, determined by radiologic evaluation&#xD;
      according to Response Evaluation Criteria in Solid Tumors (RECIST)).&#xD;
&#xD;
      Secondary objectives Secondary Objective: To determine the safety profile of a an&#xD;
      Oxaliplatin/Irinotecan/Bevacizumab therapy followed by Docetaxel/Bevacizumab therapy followed&#xD;
      by Bevacizumab until progression in terms of qualitative and quantitative toxicities from&#xD;
      first study treatment dose until completion of study treatment due to progression or for any&#xD;
      other reason.&#xD;
&#xD;
      Secondary Objective: To evaluate the study population with respect to the following: overall&#xD;
      survival (from treatment start until death from any cause) and progression free survival&#xD;
      (from treatment start until progression or death from any cause).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, multicenter, open-label, single-arm Phase II study in patients with&#xD;
      inoperable histologically proven inoperable locally advanced or metastatic gastric cancer.&#xD;
      Eligible patients must be therapy naïve and have received no previous chemotherapy or immune&#xD;
      therapy for their inoperable gastric cancer. Neo/Adjuvant Chemotherapy or adjuvant&#xD;
      Chemo/Radiotherapy are allowed. A total of 40 evaluable patients will be recruited and&#xD;
      evaluated for efficacy and safety of a sequential chemoimmunotherapy combination regime.&#xD;
&#xD;
      Overall Study Design:&#xD;
&#xD;
      Eligible patients will receive Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed&#xD;
      by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination&#xD;
      therapy cycles Bevacizumab will be continued until progression. Safety assessments will be&#xD;
      conducted in 4-weekly intervals; efficacy assessments will be conducted at 12 weekly&#xD;
      intervals, at completion of every third treatment cycle.&#xD;
&#xD;
      This study is expected to start in Q1 2009. The last patient is expected to enter the study&#xD;
      in Q2 2010, following an 18 month recruitment period. Taking into account treatment duration&#xD;
      the study is expected to end in Q4 2010. Study end will be at Last Subject Last Visit at&#xD;
      Final Staging upon disease progression. Follow-up after Last Subject Last Visit will be&#xD;
      conducted according to local standard of care thereafter, and is not part of study&#xD;
      procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">October 22, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine efficacy in terms of response rate according to RECIST criteria</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine median progression-free survival times following treatment with a chemoimmune therapy</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine overall survival time following treatment with a chemoimmune therapy</measure>
    <time_frame>3 - 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Unresectable</condition>
  <arm_group>
    <arm_group_label>interventional arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel</intervention_name>
    <arm_group_label>interventional arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Histologically proven gastric adenocarcinoma&#xD;
&#xD;
          -  Measurable or evaluable, inoperable locally advanced or metastatic disease. Presence&#xD;
             of at least one measurable lesion according to RECIST criteria.&#xD;
&#xD;
          -  No previous palliative chemotherapy and/or immunotherapy&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  ECOG performance status 0 - 2&#xD;
&#xD;
          -  Ability to understand and comply with requirements of study protocol and trial&#xD;
             participation&#xD;
&#xD;
          -  Patients of either sex are eligible for study entry. Women of childbearing potential&#xD;
             must have a negative pregnancy test at screening and must use effective contraception&#xD;
             (e.g. intrauterine device (IUD), birth control pills, or barrier device) beginning 2&#xD;
             weeks prior to first dose of study drug until 6 months after the final dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Hematological status:&#xD;
&#xD;
        Leucocytes ≥ 3 x 109/l Platelets ≥ 100 x 109/l •Renal function: Serum creatinine: ≤ 1.5 x&#xD;
        upper normal limit of normal (ULN)&#xD;
&#xD;
        •Hepatic function: AST and ALT: &lt; 2.5 x ULN or &lt; 5 x ULN if hepatic metastases are present&#xD;
        Alkaline phosphatase: &lt; 2.5 x ULN or &lt; 5 x ULN if hepatic metastases are present Total&#xD;
        bilirubin level ≤ 1.5 x ULN&#xD;
&#xD;
          -  Patient must have an INR ≤ 1.5 and aPTT ≤ 1.5 x ULN within 7 days prior to&#xD;
             randomisation&#xD;
&#xD;
          -  Baseline evaluations performed before treatment start: clinical and blood evaluations&#xD;
             no more than 7 days prior to planned first course; tumoral assessment (CT scan or MRI)&#xD;
             no more than 4 weeks prior to planned first course&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women of child-bearing potential and men not using effective contraception.&#xD;
&#xD;
          -  Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic&#xD;
             therapy) or&#xD;
&#xD;
          -  Neo/Adjuvant treatment with Irinotecan and/or docetaxel and/or Bevacizumab&#xD;
&#xD;
          -  Patients with locally advanced disease who are candidates for curative therapy&#xD;
             (including operation and/or chemotherapy and/or radiotherapy).&#xD;
&#xD;
          -  Prior history of chronic enteropathy, chronic diarrhea, unresolved bowel obstruction/&#xD;
             subobstruction, or extensive abdominopelvic radiation therapy.&#xD;
&#xD;
          -  Previous malignancy other than gastric cancer in the last 5 years except curatively&#xD;
             treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix.&#xD;
&#xD;
          -  Evidence of CNS metastasis at baseline. A CT or MRI scan within 28 days prior to&#xD;
             randomisation is mandatory to exclude CNS involvement in case of clinical suspicion of&#xD;
             CNS metastasis.&#xD;
&#xD;
          -  Peripheral neuropathy (NCI CTC grade ≥ 1).&#xD;
&#xD;
          -  Inadequate renal function:&#xD;
&#xD;
          -  adequate renal function:ould be ≥ 60 mL/min. The Cockroft and Gault formula is&#xD;
             recommended for calculation of creatinine clearance. Patients with a creatinine&#xD;
             clearance just below 60 ml/min may be eligible if a measured creatinine clearance&#xD;
             (based on 24 hour urine collection or other reliable method) is ≥ 60 mL/min.&#xD;
&#xD;
          -  Urine dipstick for proteinuria should be &lt; 2+. Patients with ≥ 2+ proteinuria on&#xD;
             dipstick urinalysis at baseline should undergo 24 hour urine collection and must&#xD;
             demonstrate &lt; 1 g of protein/24 hr.&#xD;
&#xD;
          -  Serious medical or psychiatric disorders that would interfere with the patient's&#xD;
             informed consent or compliance with the requirements of the protocol or that&#xD;
             contraindicates the use of an investigational drug or puts the patient at high risk&#xD;
             for treatment-related complications.&#xD;
&#xD;
          -  Active bacterial, viral or fungal infection (including acute or chronic-active&#xD;
             infection with HBV or HCV).&#xD;
&#xD;
          -  Acute intra abdominal inflammatory process.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg) or&#xD;
             clinically significant (i.e. active) cardiovascular disease, for example&#xD;
             cerebrovascular accidents (≤ 6 months prior to randomisation), myocardial infarction&#xD;
             (≤ 6 months prior to randomisation), unstable angina, New York Heart Association Grade&#xD;
             II or greater congestive heart failure, or serious cardiac arrhythmia uncontrolled by&#xD;
             medication or potentially interfering with protocol treatment.&#xD;
&#xD;
          -  Prior history of hypertensive crisis or hypertensive encephalopathy.&#xD;
&#xD;
          -  Evidence of tumour invading major blood vessels on imaging. The investigator or the&#xD;
             local radiologist must exclude evidence of tumour that is fully contiguous with,&#xD;
             surrounding, or extending into the lumen of a major blood vessel (e.g. pulmonary&#xD;
             artery or superior vena cava).&#xD;
&#xD;
          -  Serious uncontrolled coagulation disorder or thrombo-embolic complications (history of&#xD;
             embolisms or thromboses) within 6 months prior to study start or history of inherited&#xD;
             bleeding diathesis or coagulopathy with the risk of bleeding.&#xD;
&#xD;
          -  Major surgical procedures within 4 weeks prior to study entry or planned major&#xD;
             surgical procedures throughout the course of the study. Patients must have fully&#xD;
             recovered from any surgical procedures conducted prior to 4 weeks before study entry.&#xD;
&#xD;
          -  Minor surgery, including insertion of an indwelling catheter, within 48 hours prior to&#xD;
             the first bevacizumab infusion.&#xD;
&#xD;
          -  Concurrent or recent (within 10 days) anticoagulant therapy. Prophylactic use of&#xD;
             anticoagulants is allowed.&#xD;
&#xD;
          -  Chronic daily treatment with aspirin (&gt; 325 mg/day) or clopidogrel (&gt; 75 mg/day).&#xD;
&#xD;
          -  Chronic daily treatment with oral corticosteroids (dose of &gt; 10 mg/day&#xD;
             methylprednisolone equivalent). Inhaled steroids and short courses of oral steroids&#xD;
             for anti-emesis or as an appetite stimulant are allowed.&#xD;
&#xD;
          -  Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE).&#xD;
&#xD;
          -  Non-healing wound, active peptic ulcer or bone fracture.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 6 months of enrolment or active gastrointestinal bleeding.&#xD;
&#xD;
          -  Concurrent treatment with an investigational drug or participation in another clinical&#xD;
             trial.&#xD;
&#xD;
          -  Contraindications for the study regimen or known hypersensitivity to the study drugs&#xD;
             or to Chinese hamster ovary cell products or to other recombinant human or humanised&#xD;
             antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>AGMT Arbeitsgemeinschaft Medikamentöse Tumortherpie gemeinnützige GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Stadt Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BKH Zams</name>
      <address>
        <city>Zams</city>
        <zip>A-6511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avastin</keyword>
  <keyword>Campto</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Taxotere</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

